Literature DB >> 21447361

Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.

Golam Kibria1, Hiroto Hatakeyama, Noritaka Ohga, Kyoko Hida, Hideyoshi Harashima.   

Abstract

The objective of this study was to develop an efficient dual-ligand based PEGylated liposomal delivery system that had target specificity as well as properties that would enhance cellular uptake. PEGylated liposomes (PEG-LP) were prepared by the lipid film hydration method by adding distearoyl phosphoethanolamine-polyethylene-glycol-2000 conjugate (DSPE-PEG2000) to a lipid mixture. The cyclic RGD (Arg-Gly-Asp) peptide, a specific ligand with affinity for Integrin α(v)β(3) was coupled to the distal end of the PEG on the PEG-LP (RGD-PEG-LP). Stearylated octaarginine (STR-R8) was incorporated on the surface of the RGD-PEG-LP as dual-ligand (R8/RGD-PEG-LP) that functions as a cell penetrating peptide (CPP). RGD-PEG-LP and R8/RGD-PEG-LP were preferentially taken up by caveolae-mediated and clathrin-mediated endocytosis pathways, respectively. Compared to PEG-LP, R8/RGD-PEG-LP showed an enhanced cellular uptake as well as a higher transfection efficiency in Integrin α(v)β(3) expressing cells. However, the amount of cellular uptake or gene expression by the single ligand versions was negligible, even in Integrin α(v)β(3) expressing cells. No remarkable difference in cellular uptake or gene expression was observed for cells in which the expression of targeted receptors was absent. It can be concluded that dual-ligand modified PEG-LP possesses a strong capability for the efficient internalization of PEG-LP and consequently would be an effective tool for the targeted delivery of macromolecules or chemotherapeutics through accelerated cellular uptake.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447361     DOI: 10.1016/j.jconrel.2011.03.012

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  44 in total

1.  Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies.

Authors:  E Markoutsa; K Papadia; A D Giannou; M Spella; A Cagnotto; M Salmona; G T Stathopoulos; S G Antimisiaris
Journal:  Pharm Res       Date:  2013-12-13       Impact factor: 4.200

2.  Effect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy.

Authors:  Liyu Chen; Yanbin Liu; Weiya Wang; Kai Liu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

Review 3.  Engineering liposomal nanoparticles for targeted gene therapy.

Authors:  C Zylberberg; K Gaskill; S Pasley; S Matosevic
Journal:  Gene Ther       Date:  2017-05-15       Impact factor: 5.250

4.  Reversible Control of Spacing in Charged Lamellar Membrane Hydrogels by Hydrophobically Mediated Tethering with Symmetric and Asymmetric Double-End-Anchored Poly(ethylene glycol)s.

Authors:  Chenyu Liu; Kai K Ewert; Emily Wonder; Phillip Kohl; Youli Li; Weihong Qiao; Cyrus R Safinya
Journal:  ACS Appl Mater Interfaces       Date:  2018-12-05       Impact factor: 9.229

5.  Anti-tumor effect of RGD modified PTX loaded liposome on prostatic cancer.

Authors:  Yunjie Cao; Yaojun Zhou; Qianfeng Zhuang; Li Cui; Xianlin Xu; Renfang Xu; Xiaozhou He
Journal:  Int J Clin Exp Med       Date:  2015-08-15

6.  Advanced Functional Nanomaterials for Theranostics.

Authors:  Haoyuan Huang; Jonathan F Lovell
Journal:  Adv Funct Mater       Date:  2016-11-07       Impact factor: 18.808

7.  Dual Functionalized 5-Fluorouracil Liposomes as Highly Efficient Nanomedicine for Glioblastoma Treatment as Assessed in an In Vitro Brain Tumor Model.

Authors:  Sushant Lakkadwala; Jagdish Singh
Journal:  J Pharm Sci       Date:  2018-07-25       Impact factor: 3.534

Review 8.  Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'.

Authors:  Valery A Petrenko; James W Gillespie
Journal:  Expert Opin Drug Deliv       Date:  2016-08-05       Impact factor: 6.648

9.  EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

Authors:  Fateme Haghiralsadat; Ghasem Amoabediny; Samira Naderinezhad; Kamran Nazmi; Jantine Posthuma De Boer; Behrouz Zandieh-Doulabi; Tymour Forouzanfar; Marco N Helder
Journal:  Pharm Res       Date:  2017-11-06       Impact factor: 4.200

10.  Surface modified poly(β amino ester)-containing nanoparticles for plasmid DNA delivery.

Authors:  Rachel J Fields; Christopher J Cheng; Elias Quijano; Caroline Weller; Nina Kristofik; Nha Duong; Christopher Hoimes; Marie E Egan; W Mark Saltzman
Journal:  J Control Release       Date:  2012-10-05       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.